key: cord-0928862-pkwki4xq
authors: Diomede, Luisa; Beeg, Marten; Gamba, Alessio; Fumagalli, Oscar; Gobbi, Marco; Salmona, Mario
title: Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?
date: 2021-06-08
journal: Biomolecules
DOI: 10.3390/biom11060855
sha: 537f8f75bbf3d4a3d117ec342bb9d16dc09dad3c
doc_id: 928862
cord_uid: pkwki4xq

The phytotherapeutic properties of Glycyrrhiza glabra (licorice) extract are mainly attributed to glycyrrhizin (GR) and glycyrrhetinic acid (GA). Among their possible pharmacological actions, the ability to act against viruses belonging to different families, including SARS coronavirus, is particularly important. With the COVID-19 emergency and the urgent need for compounds to counteract the pandemic, the antiviral properties of GR and GA, as pure substances or as components of licorice extract, attracted attention in the last year and supported the launch of two clinical trials. In silico docking studies reported that GR and GA may directly interact with the key players in viral internalization and replication such as angiotensin-converting enzyme 2 (ACE2), spike protein, the host transmembrane serine protease 2, and 3-chymotrypsin-like cysteine protease. In vitro data indicated that GR can interfere with virus entry by directly interacting with ACE2 and spike, with a nonspecific effect on cell and viral membranes. Additional anti-inflammatory and antioxidant effects of GR cannot be excluded. These multiple activities of GR and licorice extract are critically re-assessed in this review, and their possible role against the spread of the SARS-CoV-2 and the features of COVID-19 disease is discussed.

In ancient times, readily available plant extracts were the first sources of "drugs". The therapeutic use of Glycyrrhiza glabra (licorice) and its extracts dates back to the dawn of time. Scholars of the history of medicine date the first information on its medicinal use to over 4000 years ago [1] . Its use has spread thanks to the ease of agricultural cultivation of its fourteen species in many warm and temperate countries. Therefore, its therapeutic use has been proposed by many cultures and ethnic groups. The study of its phytotherapeutic properties reflects the remarkable variety of products with some therapeutic activity present above all in the roots of the plant [2] [3] [4] . The pathologies for which these extracts have been used in the past are extremely varied and include disorders of the respiratory, gastrointestinal, cardiovascular, and urinary systems. It was also widely used to treat ocular exenteration and neurodegenerative diseases.

Even the toxic effects of these extracts have been duly recorded in tradition. Of interest is the hypothesis on the death of the philosopher Heraclitus of Ephesus, who had decided to eat only herbs and roots in the last part of his life. Diogenes Laertius describes his death as due to hydropsy because of his vast consumption of licorice roots [5] .

Only in the last decades, with the development of adequate analytical methods, has it become possible to understand the nature of the molecules present in the extracts. This has had decisive importance in defining the molecules' therapeutic potential. The knowledge Biomolecules 2021, 11, 855 2 of 21 from the "ancient pharmacopeia" has made it possible to identify plants with potential therapeutic activity and describe their properties in a modern, current context. Among the compounds identified, glycyrrhizic acid or glycyrrhizin (GR) and its metabolites, mainly glycyrrhetinic acid (GA) or enoxolone, are the most important [1] . Their possible pharmacological action includes the particularly important ability to act against viruses belonging to different families, including the SARS coronavirus [6, 7] . With the COVID-19 emergency and the urgent need for compounds to ease the pandemic, the antiviral properties of GR and GA, as pure substances or as components of licorice extract, have attracted fresh attention over the last year.

This review critically reassesses these aspects, widely investigated over the last year, and examines the possible utility of GR and GA against the spread of the SARS-CoV-2 virus. We have reviewed the antiviral properties of GR and GA, as pure substances or as components of licorice, from the year 1947 to the date of the search, which involved the following databases: Embase, Medline, and the Cochrane Library. Title, abstract, and keyword searches were made using Boolean search operators by extract, on the basis of a critical systematic analysis of the literature. To retrieve all the pertinent evidence, the search was done on 28 February 2021 with global geographical coverage and time limits on the ProQuest search engine: ("licorice" OR "liquorice" OR "glycyrrhiza glabra" OR "glycyrrhizic acid" OR glycyrrhizin OR "glycyrrhetinic acid" OR "enoxolone") AND (antiviral OR virus OR hepatitis). A total of 508 studies were identified after adjusting for duplicates, and then analyzed. After applying a pre-selected inclusion and exclusion criteria based on the authors' own experience, 84 original articles were deemed pertinent for inclusion in this review.

The passage from empirical and anecdotal "pharmacology and therapy" to the identification of each component of the mixture has enabled us to re-evaluate licorice extracts in modern terms and give each component potential pharmacological dignity. The identification in the extracts of licorice roots of molecules with interesting biological activities contributed to its re-evaluation ( Table 1 ). The diversity of molecules described in these extracts makes it challenging to distinguish information on their biological or pharmacological activity from anecdotal indications and scientifically proven ones [2] [3] [4] . has had decisive importance in defining the molecules' therapeutic potential. The knowledge from the "ancient pharmacopeia" has made it possible to identify plants with potential therapeutic activity and describe their properties in a modern, current context. Among the compounds identified, glycyrrhizic acid or glycyrrhizin (GR) and its metabolites, mainly glycyrrhetinic acid (GA) or enoxolone, are the most important [1] . Their possible pharmacological action includes the particularly important ability to act against viruses belonging to different families, including the SARS coronavirus [6, 7] . With the COVID-19 emergency and the urgent need for compounds to ease the pandemic, the antiviral properties of GR and GA, as pure substances or as components of licorice extract, have attracted fresh attention over the last year.

This review critically reassesses these aspects, widely investigated over the last year, and examines the possible utility of GR and GA against the spread of the SARS-CoV-2 virus. We have reviewed the antiviral properties of GR and GA, as pure substances or as components of licorice, from the year 1947 to the date of the search, which involved the following databases: Embase, Medline, and the Cochrane Library. Title, abstract, and keyword searches were made using Boolean search operators by extract, on the basis of a critical systematic analysis of the literature. To retrieve all the pertinent evidence, the search was done on 28 February 2021 with global geographical coverage and time limits on the ProQuest search engine: ("licorice" OR "liquorice" OR "glycyrrhiza glabra" OR "glycyrrhizic acid" OR glycyrrhizin OR "glycyrrhetinic acid" OR "enoxolone") AND (antiviral OR virus OR hepatitis). A total of 508 studies were identified after adjusting for duplicates, and then analyzed. After applying a pre-selected inclusion and exclusion criteria based on the authors' own experience, 84 original articles were deemed pertinent for inclusion in this review.

The passage from empirical and anecdotal "pharmacology and therapy" to the identification of each component of the mixture has enabled us to re-evaluate licorice extracts in modern terms and give each component potential pharmacological dignity. The identification in the extracts of licorice roots of molecules with interesting biological activities contributed to its re-evaluation ( Table 1 ). The diversity of molecules described in these extracts makes it challenging to distinguish information on their biological or pharmacological activity from anecdotal indications and scientifically proven ones [2] [3] [4] . We analyzed most of the data in the literature and generated a network of 21 potentially active compounds and 28 biological or pharmacological activities ( Figure 1 ). Many molecules (center of the network) share the same or similar potential activities. Particularly interesting is that the antibacterial activity is one of the primary nodes on which many licorice molecules converge. The most frequent activities are antibacterial (10 connections), neuroprotective (7 connections), antioxidant (6 connections), anti-inflammatory (6 connections), analgesic (5 connections), anticancer (5 connections). The observation that GR or its metabolites have antiviral activity is related to their antioxidant and anti-inflammatory effects, and includes the inhibition of viral internalization, downregulation of proinflammatory cytokines, inhibition of the accumulation of intracellular reactive oxygen species (ROS), inhibition of thrombin, inhibition of the hyperproduction of airway exudates, and induction of endogenous interferon (IFN). We analyzed most of the data in the literature and generated a network of 21 potentially active compounds and 28 biological or pharmacological activities ( Figure 1 ). Many molecules (center of the network) share the same or similar potential activities. Particularly interesting is that the antibacterial activity is one of the primary nodes on which many licorice molecules converge. The most frequent activities are antibacterial (10 connections), neuroprotective (7 connections), antioxidant (6 connections), anti-inflammatory (6 connections), analgesic (5 connections), anticancer (5 connections). The observation that GR or its metabolites have antiviral activity is related to their antioxidant and anti-inflammatory effects, and includes the inhibition of viral internalization, downregulation of proinflammatory cytokines, inhibition of the accumulation of intracellular reactive oxygen species (ROS), inhibition of thrombin, inhibition of the hyperproduction of airway exudates, and induction of endogenous interferon (IFN). We analyzed most of the data in the literature and generated a network of 21 potentially active compounds and 28 biological or pharmacological activities ( Figure 1 ). Many molecules (center of the network) share the same or similar potential activities. Particularly interesting is that the antibacterial activity is one of the primary nodes on which many licorice molecules converge. The most frequent activities are antibacterial (10 connections), neuroprotective (7 connections), antioxidant (6 connections), anti-inflammatory (6 connections), analgesic (5 connections), anticancer (5 connections). The observation that GR or its metabolites have antiviral activity is related to their antioxidant and anti-inflammatory effects, and includes the inhibition of viral internalization, downregulation of proinflammatory cytokines, inhibition of the accumulation of intracellular reactive oxygen species (ROS), inhibition of thrombin, inhibition of the hyperproduction of airway exudates, and induction of endogenous interferon (IFN).

We analyzed most of the data in the literature and generated a network of 21 potentially active compounds and 28 biological or pharmacological activities ( Figure 1 ). Many molecules (center of the network) share the same or similar potential activities. Particularly interesting is that the antibacterial activity is one of the primary nodes on which many licorice molecules converge. The most frequent activities are antibacterial (10 connections), neuroprotective (7 connections), antioxidant (6 connections), anti-inflammatory (6 connections), analgesic (5 connections), anticancer (5 connections). The observation that GR or its metabolites have antiviral activity is related to their antioxidant and antiinflammatory effects, and includes the inhibition of viral internalization, downregulation of pro-inflammatory cytokines, inhibition of the accumulation of intracellular reactive oxygen species (ROS), inhibition of thrombin, inhibition of the hyperproduction of airway exudates, and induction of endogenous interferon (IFN).

Today licorice is widely used as a food ingredient, flavoring agent, and dietary supplement. Licorice and its derivatives are considered "Generally Recognized as Safe" (GRAS) by the U.S. Food and Drug Administration (FDA) [8] and are also approved for use in some over-the-counter drugs [9] . Different limits for licorice consumption have been established by regulatory authorities around the world, based on the GR content. The Joint FAO/WHO Expert Committee on Food Additives (JECFA) indicated that 100 mg/day GR would be unlikely to cause adverse effects in the majority of adults [10] . The Council of Europe and the UK Food Additive and Contaminants Committee established a limit of 50 mg/kg GR [11] .

Licorice extracts, GR and GA, have been widely put to medicinal uses and some licorice-containing products are on the market. In Germany, on the basis of traditional use, aqueous licorice extracts alone or in combination with other plant-derived compounds are commercialized to support gastric function and to favor the fluidification of airway mucous [11] . Two aqueous licorice extracts containing 4.64 and 3.92 mg/mL GR have been authorized for more than 70 years as expectorants in Denmark [11] . Biomolecules 2021, 11, x FOR PEER REVIEW 7 of 20 . Figure 1 . Network of potentially active compounds and their activities in licorice root extracts. The figure illustrates the active compounds (green circles) linked to their pharmacological activities (blue circles). The network is drawn using PyGraphViz and the "fdp" layout. In this representation, the most connected nodes are close together in the center of the . The network is drawn using PyGraphViz and the "fdp" layout. In this representation, the most connected nodes are close together in the center of the network. GA and GR are the compounds with the most activities, and other compounds are on the sides of the network. GA and GR share many activities with other compounds. TPT is tetramethyl pyrazine-2,3,5,6-tetracarboxylate.

Importantly, GR is well tolerated. The expected unwanted effects of high doses, including hypertension and hypokalemia, must, however, be monitored. Oral doses up to 1500 mg of GR and 240 mg for intravenous injection have been employed [12, 13] .

The metabolism of GR from licorice extract has been investigated. Its processing starts in the oral cavity where it is partly broken down by glucuronidase, an enzyme in saliva, into glucuronic acid plus GA. In the intestine, GR is processed by bacteria-mediated hydrolysis and is mainly absorbed as GA and taken up into the liver where it is metabolized into glucuronide and sulfate conjugates. These conjugates are transported into the bile and released into the duodenum where they are again hydrolyzed to GA and subsequently reabsorbed, causing a pronounced delay in terminal plasma clearance. The intestinal metabolism means that the plasma concentration after oral GR is under the detection limit in rats and humans [14, 15] . The pharmacokinetic profile of GR after intravenous injection shows a rapid distribution phase in different animal species [13] . In humans, the volume of distribution is 60 to 80 mL/kg [12, 15] , and the maximal plasma concentration after 200 mg GR is 80 µg/mL, corresponding to 100 µM, with a terminal half-life range of 3.5 to 9 h [12, 15] .

After an oral dose of 500 to 1500 mg GA in humans, Cmax in plasma was reached after about 4 to 6 h, ranging from 3.5 to 7 µg/mL (4 to 9 µM) [13] . Elimination was biphasic at doses above 500 mg [13] with a dose-dependent second elimination phase, respectively, 11.5 and 38.7 h after 1000 and 1500 mg [13] . The slow elimination of GA in humans likely reflects tissue binding. Individual plasma profiles in humans were compatible with enterohepatic cycling [13] . GA is eliminated as glucuronide or sulfate by the bile while urinary elimination is negligible, and the latter has an anti-inflammatory action [13, 16] .

The antiviral effects of a component of Glycyrrhyza glabra were first described more than 40 years ago by Pompei and collaborators, who observed that GR inhibited the growth and cytopathology of several unrelated DNA and RNA viruses [17] . Since then, numerous studies have reported that GR and GA can act against viruses belonging to different families [18] .

In a range of concentrations from 0.025 mg/mL up to 6.7 mg/mL, GR and GA were reported active in vitro against different Herpesviridae, a large family of enveloped, doublestranded DNA viruses infecting animals and humans [17, [19] [20] [21] [22] [23] [24] . GR or aqueous licorice extracts inhibited the growth and replication of Herpes simplex virus type 1 (HSV-1), Epstein-Barr, Pseudorabies, and Varicella-zoster viruses (Table 2) [17, 19, 24] . Similar protective effects were observed in cells infected with the Paramixoviriade Newcastle or human respiratory syncytial viruses [17, 25] , or with the Rhabdoviridae vesicular stomatitis virus [17] . In these negative-strand RNA viruses, GR and aqueous licorice extract from 0.001 up to 6.7 mg/mL inhibited viral growth and increased IFN production. The growth and replication of enveloped, positive-strand RNA Flaviviridae in Japanese encephalitis, dengue, West Nile, and Yellow fever, were also reported to be inhibited by 0.1 to 2 mg/mL GR or 0.01 up to 6.7 mg/mL GA (Table 2) [26, 27] . Studies have also investigated the effects of GR on Orthomyxoviridae, negative-sense RNA viruses causing influenza in animals and humans. In cells infected with influenza virus A, a pathogen causing influenza in humans, GR from 0.2 to 0.8 mg/mL reduced infectivity and inhibited viral replication [45, 47] . In infected mice, intravenous GR, 20 mg/kg b.w., or intraperitoneal injection of 50 mg/kg b.w., lengthened survival and increased IFN-γ production [48] . In hospitalized patients with influenza and upper respiratory tract infection, the intravenous infusion of 80 mg GR reduced both the hospitalization stay and body temperature 24 h and 48 h after admission [49, 50] .

GR was reported to be effective in vitro from 0.08 to 4 mg/mL in inhibiting the replication, adsorption, and penetration of two SARS-coronaviruses (human SARS and the avian infectious bronchitis virus) [7, 51] . In cells infected with human immunodeficiency virus type 1 (HIV-1) GR and aqueous licorice extracts were reported to inhibit viral growth [22, 45, 52] .

GR's action was partially ascribed to its ability to act as a saponin, reducing cellular and viral membrane fluidity. GR has a molecular structure similar to that of cholesterol, so it may easily diffuse across the lipid bilayer, disorganizing cholesterol-containing lipid rafts, which are important in the surface attachment of the virus to the cellular plasma membrane, thus suppressing cell-to-cell fusion induced by HIV [45] .

Oral administration of a methanol-licorice extract to colostrum-deprived piglets infected with rotavirus cured diarrhea, reduced intestinal inflammation, and improved intestinal lesions [53] . GR from 0.5 to 0.7 mg/mL reduced virus penetration and proliferation in cells infected with porcine reproductive and respiratory syndrome virus, a positive-strand RNA Arteriviridae [54] . Oral treatment with 20 to 80 mg/kg b.w. glycyrrhizinate dipotassium to chicken with the viral infectious bursal disease was recently reported to stimulate immunological responses, raise IFN levels, and reduce viral load [55] .

The main antiviral activity of GR investigated and described is against hepatitis viruses A, B, and C [27] [28] [29] [30] [31] [32] [33] . This stems from the observation in Japan, where licoricederived compounds were traditionally used as antiallergic agents, that GR infused into patients suffering from allergic hepatitis had positive effects on transaminase levels [56] . GR and GA were then employed in clinical practice to treat liver diseases, notably chronic viral hepatitis. A pharmacological formulation called Stronger Neo-Minophagen C (SNMC), containing 0.2% (4 mg) GA as the main active constituent, 2% (40 mg) glycine, and 0.1% (2 mg) cysteine in 20 mL ampules, was developed and has been widely used in Japan and throughout East Asia over the past 30 years to treat chronic hepatitis B or C and cirrhosis ( Table 2) [33] [34] [35] 42] . Its use in the rest of the world is more restricted [33] . Clinical studies in patients with chronic hepatitis indicated that short-or long-term usage of SNMC is effective in reducing viral load, improving the liver histopathological features, and reducing transaminases, with no noteworthy side effects (Table 2) [28, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . These properties result in a reduced risk of cirrhosis and hepatocellular carcinoma [43] .

The mechanisms involved in the ability of GR to improve liver biochemistry and histology are not fully understood. Pharmacokinetic investigations indicate that the bioavailability of intravenous GR correlates with the functional capacity of the liver. In fact, the half-life and the total body clearance of GR were greater in patients with hepatitis than in healthy subjects [12] . GR dose-dependently inhibited the expression of hepatitis A virus antigen and reduced infectivity in the human hepatoma cell line PLC/PRF/5 without causing cytotoxicity [27] (Figure 2 ). GR also inhibited the entry of the virus into the cells, which occurs through receptor-mediated endocytosis [27] . This effect was ascribed to GR's ability to interact with cell membranes, reducing both the fluidity and the negative surface charge (Figure 2 ). Experiments on isolated rat hepatocytes indicated that GR lowers the release of the enzyme aspartate aminotransferase and inhibits the activation of phospholipase A2, both involved in the cell membrane lysis [28] . In addition to the anti-viral and cytoprotective effects, GR and GA were found to display marked anti-inflammatory and immunomodulatory activities mediated by multiple mechanisms. Bacterial and viral infections activate the toll-like receptor 4 (TLR4) signaling pathway, leading to an increased production of pro-inflammatory cytokines, such as nuclear factor-κB, tumor necrosis factor, interleukin (IL)-1, and IL-6 [57] . GR and GA can interfere with the TLR4 activation and inhibit inflammation by different mechanisms. They may directly reduce the expression/activation of the TLR4 receptor thus suppressing cytokine production and inflammatory mediators. In addition, GR and GA may bind to proteins named high-mobility group box 1, directly activated by the TLR4 pathway to mediate the production and release of cytokines and chemokines [57] . Finally, GR and GA are also reported to increase the secretion of IFN, helping the prevention of viral attachment [58] . All these activities resulted in the improvement of the immunological status of patients with hepatitis B and the increase in the antigen's immunogenicity [31] (Figure 2 ). Based on the findings in mice infected with influenza A virus [48] , it was hypothesized that GR may protect against the damage caused by hepatitis viruses by inducing the production of IFN, causing cytokines secreted by infected cells of the immune system to respond to infectious agents. All these findings supported the potential use of GR in patients with hepatitis who do not respond to IFN therapy.

The antiviral activities of GR in general and specifically for SARS-CoV, suggest its potential use in treating COVID-19. In 2003, Cinatl et al. showed that GR hinders the internalization of the SARS-CoV-1 virus in a concentration-dependent manner, with an IC50 of 300 µM [6] . Though the mechanism of action is not clear, it seems that GR is a multitargeting compound, interacting with various viral and cellular processes important for viral internalization and replication [57, 59] .

The internalization of the SARS-CoV-2 virus to the host cell starts with the viral spike protein binding to the cellular receptor angiotensin-converting enzyme 2 (ACE2) (Figure In addition to the anti-viral and cytoprotective effects, GR and GA were found to display marked anti-inflammatory and immunomodulatory activities mediated by multiple mechanisms. Bacterial and viral infections activate the toll-like receptor 4 (TLR4) signaling pathway, leading to an increased production of pro-inflammatory cytokines, such as nuclear factor-κB, tumor necrosis factor, interleukin (IL)-1, and IL-6 [57] . GR and GA can interfere with the TLR4 activation and inhibit inflammation by different mechanisms. They may directly reduce the expression/activation of the TLR4 receptor thus suppressing cytokine production and inflammatory mediators. In addition, GR and GA may bind to proteins named high-mobility group box 1, directly activated by the TLR4 pathway to mediate the production and release of cytokines and chemokines [57] . Finally, GR and GA are also reported to increase the secretion of IFN, helping the prevention of viral attachment [58] . All these activities resulted in the improvement of the immunological status of patients with hepatitis B and the increase in the antigen's immunogenicity [31] (Figure 2 ). Based on the findings in mice infected with influenza A virus [48] , it was hypothesized that GR may protect against the damage caused by hepatitis viruses by inducing the production of IFN, causing cytokines secreted by infected cells of the immune system to respond to infectious agents. All these findings supported the potential use of GR in patients with hepatitis who do not respond to IFN therapy.

The antiviral activities of GR in general and specifically for SARS-CoV, suggest its potential use in treating COVID-19. In 2003, Cinatl et al. showed that GR hinders the internalization of the SARS-CoV-1 virus in a concentration-dependent manner, with an IC 50 of 300 µM [6] . Though the mechanism of action is not clear, it seems that GR is a multi-targeting compound, interacting with various viral and cellular processes important for viral internalization and replication [57, 59] .

The internalization of the SARS-CoV-2 virus to the host cell starts with the viral spike protein binding to the cellular receptor angiotensin-converting enzyme 2 (ACE2) ( Figure 3 ) [60] . Once bound to the cell surface of the host, via ACE2, the spike protein is then cleaved by the host transmembrane serine protease 2 (TMPRSS2) into the S1/S2 domain. The S1 domain contains the receptor-binding domain (RBD) which binds directly to ACE2. After cleavage of the spike protein, the virus is internalized by the cell by viral and cellular membrane fusion. 3) [60] . Once bound to the cell surface of the host, via ACE2, the spike protein is then cleaved by the host transmembrane serine protease 2 (TMPRSS2) into the S1/S2 domain. The S1 domain contains the receptor-binding domain (RBD) which binds directly to ACE2. After cleavage of the spike protein, the virus is internalized by the cell by viral and cellular membrane fusion. This step is followed by the expression and replication of the viral genomic RNA which are incorporated into newly produced viral particles. Replication is mediated by several proteases, and 3-chymotrypsin-like cysteine protease (3CLpro or MPro) enzyme is one of the key players sustaining the viral life cycle [60] . The newly formed virions are then transported to the cell surface and released by exocytosis into the extracellular space ( Figure 3 ).

Several in silico docking studies suggested a direct interaction of GR and GA to these key players in virus internalization and replication: ACE2 [61] [62] [63] , spike protein and its RBD [63] [64] [65] [66] , and 3CLPro [63, 65, [67] [68] [69] [70] [71] [72] [73] [74] . Only a few in silico analyses were negative (3CLpro [68, 75] , Spike [76] ).

The main protease 3CLpro contains several canonical binding pockets, denoted P1-P4, in its active site [77] . In silico studies suggest the binding of GR to these pockets [63, [67] [68] [69] [70] [71] [72] [73] [74] . However, when tested on enzyme activity, the results were contradictory. GR was not present among the active compounds in a large-scale high-throughput in vitro study (i.e., it did not inhibit the enzyme activity by 60% at a concentration of 50 µM) [77] , though a recent study showed a 70% inhibition of the enzyme activity with 30 µM GR [78] . The same authors showed that the IC50 of GR in a Vero E6 cell infection assay was around 500 µM, possibly suggesting limited internalization of GR.

Mahdian et al. suggested different potential binding pockets for GR, both on the spike protein (on RBD and in another domain close to the S1/S2 cleavage site), and on ACE2 (in a domain close to the interface where RBD binds) [63] . GR binding to RBD and to the S1 spike subdomain was also suggested by Yu et al. based on in silico data [64] . These authors, however, provided experimental support too, although not so definite. They employed surface plasmon resonance (SPR), a technique widely used to study interactions between unlabeled molecules and determine their binding constants [79] . SPR indicated relatively high-affinity binding of GR to the S1 domain (Kd 0.87 µM) [64] , while a binding inhibition assay based on nanobeads showed more than 20 times lower affinity (IC50 22 µM). Another study investigated the GR binding to the S2 domain and ACE2, in silico with positive docking results, and experimentally by SPR [80] . In this case, however, the affinity estimated by SPR was very low (Kd more than 2 mM) suggesting a nonspecific interaction. This step is followed by the expression and replication of the viral genomic RNA which are incorporated into newly produced viral particles. Replication is mediated by several proteases, and 3-chymotrypsin-like cysteine protease (3CLpro or MPro) enzyme is one of the key players sustaining the viral life cycle [60] . The newly formed virions are then transported to the cell surface and released by exocytosis into the extracellular space ( Figure 3 ).

Several in silico docking studies suggested a direct interaction of GR and GA to these key players in virus internalization and replication: ACE2 [61] [62] [63] , spike protein and its RBD [63] [64] [65] [66] , and 3CLPro [63, 65, [67] [68] [69] [70] [71] [72] [73] [74] . Only a few in silico analyses were negative (3CLpro [68, 75] , Spike [76] ).

The main protease 3CLpro contains several canonical binding pockets, denoted P1-P4, in its active site [77] . In silico studies suggest the binding of GR to these pockets [63, [67] [68] [69] [70] [71] [72] [73] [74] . However, when tested on enzyme activity, the results were contradictory. GR was not present among the active compounds in a large-scale high-throughput in vitro study (i.e., it did not inhibit the enzyme activity by 60% at a concentration of 50 µM) [77] , though a recent study showed a 70% inhibition of the enzyme activity with 30 µM GR [78] . The same authors showed that the IC 50 of GR in a Vero E6 cell infection assay was around 500 µM, possibly suggesting limited internalization of GR.

Mahdian et al. suggested different potential binding pockets for GR, both on the spike protein (on RBD and in another domain close to the S1/S2 cleavage site), and on ACE2 (in a domain close to the interface where RBD binds) [63] . GR binding to RBD and to the S1 spike subdomain was also suggested by Yu et al. based on in silico data [64] . These authors, however, provided experimental support too, although not so definite. They employed surface plasmon resonance (SPR), a technique widely used to study interactions between unlabeled molecules and determine their binding constants [79] . SPR indicated relatively high-affinity binding of GR to the S1 domain (Kd 0.87 µM) [64] , while a binding inhibition assay based on nanobeads showed more than 20 times lower affinity (IC 50 22 µM). Another study investigated the GR binding to the S2 domain and ACE2, in silico with positive docking results, and experimentally by SPR [80] . In this case, however, the affinity estimated by SPR was very low (Kd more than 2 mM) suggesting a nonspecific interaction.

The interaction of GR with ACE2 was also investigated [62] . SPR studies indicated a Kd of 4.4 µM, but the enzymatic activity of ACE2 was not affected, suggesting that it does not bind to the catalytic domain [62] . The docking results did indicate that GR binds to a domain of ACE2 close to the binding site responsible for the interaction with RBD, thus suggesting that it might interfere with the spike protein-mediated interaction of the virus with the host cells. However, this has not been demonstrated experimentally: Xu et al. did not observe any effect of GR, up to 100 µM, on viral internalization in HEK293T cells [81] , in line with the results shown by Sand et al. in Vero E6 cells (IC 50 500 µM) [78] .

On the basis of the findings by these different authors, indicating that GR activity varied by some orders of magnitude, one can hypothesize that the molecule has to penetrate the cell to reach a reasonably high concentration to be effective.

Another mechanism by which a compound might hinder viral internalization is the reduction of ACE2 on the cell surface. GR inhibits the expression of ACE2 due to a reduction in the signaling activity of the high mobility group box 1 complex in a dose-and time-dependent manner [62] . GR may also reduce SARS-CoV-2 infectivity by inhibiting the lipid-dependent attachment of the virus to host cells, as for other viruses [57] . However, no experimental data are available to support this hypothesis.

Recent evidence suggests that TLR4 can strongly interact with the spike protein of SARS-CoV-2 and induce an inflammatory signaling pathway which results in an increased expression of ACE2 [82] . It cannot be excluded that GR and GA may prevent viral infection by blocking TLR4 and thus ACE2 expression [82] .

Even though many in silico studies suggest that GR interacts with proteins involved in SARS-CoV-2 virus infection and reproduction, supporting in vivo and in vitro data are scarce, even more so for GA, the main GR metabolite. There is only one in silico study suggesting GA binding to the protease 3CLPro [69] .

GR and GA are also included in the ReFRAME library [83] , a library of 12,000 compounds used for drug repositioning screening. When these compounds were tested at a concentration of 5 µM for inhibition of viral infection in Vero E6 cells, GR and GA were not among those active [84, 85] .

The interest in licorice extract to prevent or treat COVID-19 is also justified by its anti-inflammatory and antiallergic actions [57, 82, 86] , which have been attributed to the corticosteroid-like activity of GR and GA [11] . Licorice has been employed to treat dry cough and chronic obstructive lung diseases due to GR's ability to reduce tracheal spasm induced by histamine, and to its antitussive and expectorant properties [11] .

Based on these findings and the known ability of GR and GA to boost IFN secretion, with anti-inflammatory effects, two clinical trials have been launched on the effects of licorice extracts on clinical symptoms in COVID-19 patients. One is a pilot, single-center, non-randomized trial, registered on ClinicalTrial.gov (NCT04487964), testing the effects of licorice extracts administered together with Boswellia serrata gum as complementary medicine in Egyptian patients with COVID-19. In addition to conventional therapy, patients receive one capsule twice daily containing 250 mg of standardized licorice extract, corresponding to 62.5 mg GR, for 10 days, and 2 g four times daily for 15 days of Boswellia gum resin. The other is a single-center, open-label, randomized clinical trial with parallel-group design, registered in the Iranian Registry of Clinical trials (IRCT20200506047323N2) which will look at the effects of licorice root extracts in moderately ill patients with pneumonia from COVID-19 [87] . In addition to the standard treatment, D-REGLIS tablets containing 380 mg of standardized dry extract of licorice with less than 3% GR at a dose of 760 mg were given three times a day for 14 days. No results have been published yet. Data Availability Statement: This is a Review of the data available in literature. No data were analysed or generated during the study.

This study is part of a more than 30-year collaboration between Perfetti Van Melle S.P.A. and the Istituto di Ricerche Farmacologiche Mario Negri IRCCS (IRFMN). It essentially concerns scientific support for the group's activities with particular regard to product safety, the working environment, and updating of legislation. M.S., L.D., M.G., O.F., A.G. and M.B. are employees of IRFMN. The authors declare no conflict of interest. Perfetti Van Melle S.P.A. has no role in the collection, analyses, and interpretation of data, in the writing of the manuscript, or in the decision to publish the results. 

A History of the Therapeutic Use of Liquorice in Europe

Prospects for the Creation of New Antiviral Drugs Based on Glycyrrhizic Acid and Its Derivatives (a Review)

Review of Pharmacological Effects of Glycyrrhiza sp. and Its Bioactive Compounds

Glycyrrhiza Glabra): A Phytochemical and Pharmacological Review

A Hypothesis on the Death of the Greek Philosopher Heraclitus

Glycyrrhizin, an Active Component of Liquorice Roots, and Replication of SARS-Associated Coronavirus

In Vitro Susceptibility of 10 Clinical Isolates of SARS Coronavirus to Selected Antiviral Compounds

CFR 184-Direct Food Substances Affirmed as Generally Recognized as Safe-Content Details-CFR-2011-Title21-Vol3-Part184

Biomolecules 2021

CFR-Code of Federal Regulations Title 21

Joint FAO/WHO Expert Committee on Food Additives. Evaluation of Certain Food Additives: Sixty-Third Report of the Joint FAO/WHO Expert Committee on Food Additives

Assessment Report on Glycyrrhiza glabra L. and/or Glycyrrhiza Inflata Bat and/or Glycyrrhiza uralensis Fisch, Radix

Pharmacokinetics of Intravenous Glycyrrhizin after Single and Multiple Doses in Patients with Chronic Hepatitis C Infection

Analysis and Pharmacokinetics of Glycyrrhizic Acid and Glycyrrhetinic Acid in Humans and Experimental Animals

Improvement of Selectivity and Sensitivity by Column Switching in the Determination of Glycyrrhizin and Glycyrrhetic Acid in Human Plasma by High-Performance Liquid Chromatography

Pharmacokinetic Profile of Glycyrrhizin in Healthy Volunteers by a New High-Performance Liquid Chromatographic Method

Human Metabolism of Orally Ingested Glycyrrhetinic Acid and Monoammonium Glycyrrhizinate

Glycyrrhizic Acid Inhibits Virus Growth and Inactivates Virus Particles

Antiviral Effects of Glycyrrhiza Species

Antiviral Effect of Diammonium Glycyrrhizinate and Lithium Chloride on Cell Infection by Pseudorabies Herpesvirus

Enhancement of Anti-Herpetic Activity of Glycyrrhizic Acid by Physiological Proteins

The Effect of Aqueous Extract of Glycyrrhiza Glabra on Herpes Simplex Virus 1

Antiviral and Antitumor Activity of Licorice Root Extracts

Inhibitory Effects of Some Derivatives of Glycyrrhizic Acid against Epstein-Barr Virus Infection: Structure-Activity Relationships

Antiviral Activity of Liquorice Powder Extract against Varicella Zoster Virus Isolated from Egyptian Patients

Water Extract of Licorice Had Anti-Viral Activity against Human Respiratory Syncytial Virus in Human Respiratory Tract Cell Lines

Ammonium Salt of Glycyrrhizic Acid as an Antiviral

Inhibition of Hepatitis A Virus Replication In Vitro by Antiviral Compounds

Efficacy of Intravenous Glycyrrhizin in the Early Stage of Acute Onset Autoimmune Hepatitis

Studies on Mechanism of Action of Glycyrrhizin against Hepatitis A Virus Replication in Vitro

Effect of Glycyrrhizin on Lysis of Hepatocyte Membranes Induced by Anti-Liver Cell Membrane Antibody

Effects of Glycyrrhizin on Hepatitis B Surface Antigen: A Biochemical and Morphological Study

Therapeutic Basis of Glycyrrhizin on Chronic Hepatitis B

Experience in Germany with Glycyrrhizinic Acid for the Treatment of Chronic Viral Hepatitis

Intravenous Glycyrrhizin Improved Serum Transaminases Rapidly in a Chronic Hepatitis B Patient with Acute Exacerbation

The Therapeutic Effects of Stronger Neo Minophage

Biomolecules 2021

Effects of Glycyrrhizin on Biochemical Tests in Patients with Chronic Hepatitis. Double Blind Trial

Clinical and Laboratory Observation on the Effect of Glycyrrhizin in Acute and Chronic Viral Hepatitis

Effects of Glycyrrhizin Therapy on Liver Histology in Chronic Aggressive Hepatitis. New Trends in Peptic Ulcer and Chronic Hepatitis

The Long Term Efficacy of Glycyrrhizin in Chronic Hepatitis C Patients

Long-Term Treatment of Chronic Hepatitis C with Glycyrrhizin (Stronger Neo-Minophagen C (SNMC)) for Preventing Liver Cirrhosis and Hepatocellular Carcinoma

Biochemical and Histological Effects of 26 Weeks of Glycyrrhizin Treatment in Chronic Hepatitis C: A Randomized Phase II Trial

A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients

Review Article: Glycyrrhizin as a Potential Treatment for Chronic Hepatitis C

Ribavirin, 6-Azauridine and Glycyrrhizin: Antiviral Compounds Active against Pathogenic Flaviviruses

The Broad Anti-Viral Agent Glycyrrhizin Directly Modulates the Fluidity of Plasma Membrane and HIV-1 Envelope

Glycyrrhizin Inhibits Influenza A Virus Uptake into the Cell

Glycyrrhizic Acid Derivatives as Influenza A/H1N1 Virus Inhibitors

Interferon Induction by Glycyrrhizin and Glycyrrhetinic Acid in Mice

Effects and Cost of Glycyrrhizin in the Treatment of Upper Respiratory Tract Infections in Members of the Japanese Maritime Self-Defense Force: Preliminary Report of a Prospective, Randomized, Double-Blind, Controlled, Parallel-Group, Alternate-Day Treatment Assignment Clinical Trial

Prevention and Treatment of Influenza, Influenza-Like Illness, and Common Cold by Herbal, Complementary, and Natural Therapies

Synthesis and Antiviral Activity of 18α-Glycyrrhizic Acid and Its Esters

Anti-Rotaviral Effects of Glycyrrhiza Uralensis Extract in Piglets with Rotavirus Diarrhea

Suppression of Porcine Reproductive and Respiratory Syndrome Virus Proliferation by Glycyrrhizin

Antiviral and Immunomodulatory Effects of Dipotassium Glycyrrhizinate in Chicks Artificially Infected with Infectious Bursal Disease Virus. Pak

Treatment of Hepatitis with the Antiallergic Drug, Stronger Neo-Minophagen C

Glycyrrhizin: An Alternative Drug for the Treatment of COVID-19 Infection and the Associated Respiratory Syndrome?

Botanical Drugs and Supplements Affecting the Immune Response in the Time of COVID-19: Implications for Research and Clinical Practice

Advances in Research on ACE2 as a Receptor for 2019-NCoV

Potential Natural Compounds for Preventing SARS-CoV-2 (2019-NCoV) Infection. Preprints 2020

Identifying Potential Anti-COVID-19 Pharmacological Components of Traditional Chinese Medicine Lianhuaqingwen Capsule Based on Human Exposure and ACE2 Biochromatography Screening

Drug Repurposing Using Computational Methods to Identify Therapeutic Options for COVID-19

Glycyrrhizic Acid Exerts Inhibitory Activity against the Spike Protein of SARS-CoV-2

Virtual Screening of Plant-Derived Compounds against SARS-CoV-2 Viral Proteins Using Computational Tools

Hijacking SARS-CoV-2/ACE2 Receptor Interaction by Natural and Semi-Synthetic Steroidal Agents Acting on Functional Pockets on the Receptor Binding Domain

An Investigation into the Identification of Potential Inhibitors of SARS-CoV-2 Main Protease Using Molecular Docking Study

Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies

Drug Repurposing Studies Targeting SARS-CoV-2: An Ensemble Docking Approach on Drug Target 3C-like Protease (3CLpro)

Tung Ngo, S. Rapid Prediction of Possible Inhibitors for SARS-CoV-2 Main Protease Using Docking and FPL Simulations

Molecular Docking, Binding Mode Analysis, Molecular Dynamics, and Prediction of ADMET/Toxicity Properties of Selective Potential Antiviral Agents against SARS-CoV-2 Main Protease: An Effort toward Drug Repurposing to Combat COVID-19

Molecular Docking Analysis of Selected Natural Products from Plants for Inhibition of SARS-CoV-2 Main Protease

Potential Role of Medicinal Plants and Their Constituents in the Mitigation of SARS-CoV-2: Identifying Related Therapeutic Targets Using Network Pharmacology and Molecular Docking Analyses

Molecular Docking and ADMET Study of Bioactive Compounds of Glycyrrhiza Glabra against Main Protease of SARS-CoV2

X-Ray Screening Identifies Active Site and Allosteric Inhibitors of SARS-CoV-2 Main Protease

Repurposing Approved Drugs as Inhibitors of SARS-CoV-2 S-Protein from Molecular Modeling and Virtual Screening

Structure of M pro from SARS-CoV-2 and Discovery of Its Inhibitors

Glycyrrhizin Effectively Neutralizes SARS-CoV-2 in Vitro by Inhibiting the Viral Main Protease

Looking towards Label-Free Biomolecular Interaction Analysis in a High-Throughput Format: A Review of New Surface Plasmon Resonance Technologies

Eltrombopag Is a Potential Target for Drug Intervention in SARS-CoV-2 Spike Protein

Improved Protein Structure Prediction by Deep Learning Irrespective of Co-Evolution Information

Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection? Front. Immunol. 2020, 11

The ReFRAME Library as a Comprehensive Drug Repurposing Library and Its Application to the Treatment of Cryptosporidiosis

Oral Drug Repositioning Candidates and Synergistic Remdesivir Combinations for the Prophylaxis and Treatment of COVID-19

Discovery of SARS-CoV-2 Antiviral Drugs through Large-Scale Compound Repurposing

Glycyrrhizin: An Old Weapon against a Novel Coronavirus

Effects of Licorice on Clinical Symptoms and Laboratory Signs in Moderately Ill Patients with Pneumonia from COVID-19: A Structured Summary of a Study Protocol for a Randomized Controlled Trial